Advanced Prostate Cancer

Advanced Prostate Cancer/

Understanding How Personalized Medicine Is Developed By Way Of A Real Situation – Olaparib

It is common knowledge that men with metastatic castration-resistant prostate cancer (CRPC) don’t all have the same disease. There are many different types or flavors of prostate cancer.

These differences are involved in the genetic structure of the cancer cell its self. Some prostate cancers have mutations in the DNA repair genes (genes whose job is to repair other gene mutations). It has been shown that prostate cancer that have these mutations are more likely to respond to the poly(ADP-ribose) polymerase (PARP) inhibitor olaparib. (Currently olaparib is FDA approved for certain types of advanced ovarian cancers.)

In […]

Using Circulating Tumor Cells To Evaluate Chemotherapy Efficacy Leading To Improved Clinical Decision Making

Today most doctors rely on their personal evaluation or objective response criteria (OR) of a man to know when docetaxel chemotherapy has stopped working. The earlier this determination can be accurately made the quicker an alternative treatment can e put into place. Personal evaluations without any validated tools are unreliable and never consistent among doctors. Errors are made which will lead to poorer outcomes.

Circulating tumor cell (CTC) counts have been looked at and seem to yield positive results for making this type of clinical decision in men who are taking both abiraterone (Zytiga) and enzalutamide (Xtandi). […]

By |April 23rd, 2015|CTCs, docetaxel, prognostic tools, Research|0 Comments

Clinical Trial Evaluates Hormone Therapy With And Without Zoledronic Acid In Men With Prostate Cancer And Bone Metastases Who Are Treatment-Naïve

Zoledronic acid (ZA) is considered the standard of care to prevent skeletal-related events (SREs) in men with castration-resistant prostate cancer and bone metastases. The question that still remains is when to start the ZA.

In a phase III clinical trial a total of 227 men with hormonal treatment-naïve prostate cancer and bone metastases were randomly assigned in a 1:1 ratio to receive zoledronic acid along with ADT (LH-RH analogue + bicalutamide) or ADT alone.

After a median follow-up of 41.1 months it was found that in men with hormonal treatment naïve prostate cancer with bone metastases, concurrent use of ZA […]

Prostate Cancer Kills Black Men at Twice the Rate as White Men

African American men suffer from Prostate Cancer more than anyone, anywhere. If we want better treatments, then we’ve got to tell folks what it means to be a African American man diagnosed with Prostate Cancer. Please go to http://twiceasmany.org/prostate_cancer_story/ and write a few paragraphs about your experience with prostate cancer OR email twiceasmany@malecare.org and we’ll set up a time for a telephone interview.

The stories we collect will be used for support, advocacy and promotion of research into why Prostate Cancer kills African American men at more than twice the rate as white men.

By |April 22nd, 2015|Politics of Cancer, Research|0 Comments